Cytokinetics (CYTK) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $61.95, -3.08% vs the prior close of $63.92.
- Volume 1.20M shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CYTK slides 3.1% to $61.95. Closed at $61.95, -3.08% vs the prior close of $63.92. Day range $61.69–$63.90, opened at $63.90.
CYTK daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CYTK slides 3.1% to $61.95
- Closed at $61.95, -3.08% vs the prior close of $63.92. Day range $61.69–$63.90, opened at $63.90.
- Volume was 1.20M shares, 0.6x its 50-day average of 2.04M — lighter than usual.
- Price is -11.8% vs its 50-day average ($70.26) and -11.7% vs its 200-day average ($70.14).
- 52-week range $54.30–$88.31; today's close sits at 22% of that range, 29.8% below the 52-week high.
Oct 15, 2026 — CYTK rises 0.8% to $63.92
- Closed at $63.92, +0.77% vs the prior close of $63.43. Day range $63.81–$65.57, opened at $64.81.
- Volume was 1.67M shares, 0.8x its 50-day average of 2.04M.
- Price is -9.5% vs its 50-day average ($70.65) and -8.9% vs its 200-day average ($70.13).
- 52-week range $54.30–$88.31; today's close sits at 28% of that range, 27.6% below the 52-week high.
Oct 14, 2026 — CYTK rises 2.9% to $63.43
- Closed at $63.43, +2.94% vs the prior close of $61.62. Day range $60.99–$64.01, opened at $61.62.
- Volume was 2.10M shares, 1.0x its 50-day average of 2.05M.
- Price is -10.6% vs its 50-day average ($70.95) and -9.5% vs its 200-day average ($70.12).
- 52-week range $54.30–$88.31; today's close sits at 27% of that range, 28.2% below the 52-week high.
Oct 13, 2026 — CYTK dips 1.9% to $61.62
- Closed at $61.62, -1.86% vs the prior close of $62.79. Day range $61.50–$63.05, opened at $62.32.
- Volume was 1.94M shares, 0.9x its 50-day average of 2.05M.
- Price is -13.5% vs its 50-day average ($71.25) and -12.1% vs its 200-day average ($70.12).
- 52-week range $54.30–$88.31; today's close sits at 22% of that range, 30.2% below the 52-week high.
Oct 12, 2026 — CYTK ends flat (-0.2%) to $62.79
- Closed at $62.79, -0.19% vs the prior close of $62.91. Day range $62.13–$63.50, opened at $62.48.
- Volume was 1.25M shares, 0.6x its 50-day average of 2.06M.
- Price is -12.2% vs its 50-day average ($71.55) and -10.5% vs its 200-day average ($70.14).
- 52-week range $54.30–$88.31; today's close sits at 25% of that range, 28.9% below the 52-week high.
Oct 9, 2026 — CYTK rises 1.5% to $62.91
- Closed at $62.91, +1.45% vs the prior close of $62.01. Day range $61.59–$63.03, opened at $61.87.
- Volume was 1.12M shares, 0.5x its 50-day average of 2.08M — lighter than usual.
- Price is -12.4% vs its 50-day average ($71.83) and -10.3% vs its 200-day average ($70.14).
- 52-week range $54.30–$88.31; today's close sits at 25% of that range, 28.8% below the 52-week high.
Oct 8, 2026 — CYTK rises 1.5% to $62.01
- Closed at $62.01, +1.46% vs the prior close of $61.12. Day range $59.79–$62.79, opened at $60.31.
- Volume was 2.59M shares, 1.3x its 50-day average of 2.06M.
- Price is -14.1% vs its 50-day average ($72.18) and -11.6% vs its 200-day average ($70.15).
- 52-week range $54.30–$88.31; today's close sits at 23% of that range, 29.8% below the 52-week high.
Oct 7, 2026 — CYTK dips 0.4% to $61.12, a 3-month low, 5 down days in a row
- Closed at $61.12, -0.37% vs the prior close of $61.35. Day range $60.15–$62.05, opened at $61.09.
- Volume was 2.40M shares, 1.2x its 50-day average of 2.05M.
- Price is -15.7% vs its 50-day average ($72.51) and -12.9% vs its 200-day average ($70.15).
- 52-week range $54.30–$88.31; today's close sits at 20% of that range, 30.8% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — CYTK dips 2.2% to $61.35, a 3-month low, 4 down days in a row
- Closed at $61.35, -2.15% vs the prior close of $62.70. Day range $60.68–$62.53, opened at $62.20.
- Volume was 3.23M shares, 1.6x its 50-day average of 2.02M.
- Price is -15.8% vs its 50-day average ($72.88) and -12.6% vs its 200-day average ($70.16).
- 52-week range $54.30–$88.31; today's close sits at 21% of that range, 30.5% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — CYTK slides 4.4% to $62.70, a 3-month low, 3 down days in a row
- Closed at $62.70, -4.42% vs the prior close of $65.60. Day range $62.19–$65.76, opened at $65.60.
- Volume was 3.23M shares, 1.6x its 50-day average of 1.99M.
- Price is -14.4% vs its 50-day average ($73.26) and -10.6% vs its 200-day average ($70.15).
- 52-week range $54.30–$88.31; today's close sits at 25% of that range, 29.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — CYTK ends flat (-0.0%) to $65.60
- Closed at $65.60, -0.03% vs the prior close of $65.62. Day range $64.49–$66.91, opened at $66.45.
- Volume was 2.65M shares, 1.4x its 50-day average of 1.96M.
- Price is -10.9% vs its 50-day average ($73.62) and -6.5% vs its 200-day average ($70.15).
- 52-week range $54.30–$88.31; today's close sits at 33% of that range, 25.7% below the 52-week high.
CYTK latest news & SEC filings
Every SEC filing by or about CYTK in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Blum Robert I converted options/RSUs into 7,500 shares at $10.60 (≈$79.50K) on Oct 12, 2026; now holds 286,044
- Blum Robert I sold 7,500 shares at $62.88 (≈$471.60K) on Oct 12, 2026; now holds 278,544
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Malik Fady Ibraham converted options/RSUs into 3,500 shares at $7.80 (≈$27.30K) on Oct 6, 2026; now holds 157,402
- Malik Fady Ibraham sold 3,500 shares at $61.38 (≈$214.83K) on Oct 6, 2026; now holds 153,902
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Blum Robert I converted options/RSUs into 7,500 shares at $10.60 (≈$79.50K) on Sep 28, 2026; now holds 286,044
- Blum Robert I sold 7,500 shares at $65.46 (≈$490.95K) on Sep 28, 2026; now holds 278,544
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Malik Fady Ibraham converted options/RSUs into 3,500 shares at $7.80 (≈$27.30K) on Sep 22, 2026; now holds 157,402
- Malik Fady Ibraham sold 3,500 shares at $68.29 (≈$239.02K) on Sep 22, 2026; now holds 153,902
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $28.62M (prior year $66.77M) (-57.1% vs Jun 30, 2025)
- Net income: -$198.76M (prior year -$134.37M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.50 (prior year -$1.12) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade CYTK
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 24, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.44% (largest 4.4%).
- Liquidity: about 2.13M shares (≈$131.67M) trade per day on average.
- 52-week position: $61.95 vs a range of $54.30–$88.31 (22% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Robert I Blum sold 7,500 shares on Sep 28, 2026.
- Latest filings: 8-K Aug 28, 2026; 8-K Aug 13, 2026; 10-Q Aug 6, 2026.
- Share count: 139.02M shares outstanding (Aug 4, 2026), +16.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CYTK market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 63.90 | 63.90 | 61.69 | 61.95 | 1.20M |
| Oct 15, 2026 | 64.81 | 65.57 | 63.81 | 63.92 | 1.67M |
| Oct 14, 2026 | 61.62 | 64.01 | 60.99 | 63.43 | 2.10M |
| Oct 13, 2026 | 62.32 | 63.05 | 61.50 | 61.62 | 1.94M |
| Oct 12, 2026 | 62.48 | 63.50 | 62.13 | 62.79 | 1.25M |
| Oct 9, 2026 | 61.87 | 63.03 | 61.59 | 62.91 | 1.12M |
| Oct 8, 2026 | 60.31 | 62.79 | 59.79 | 62.01 | 2.59M |
| Oct 7, 2026 | 61.09 | 62.05 | 60.15 | 61.12 | 2.40M |
| Oct 6, 2026 | 62.20 | 62.53 | 60.68 | 61.35 | 3.23M |
| Oct 5, 2026 | 65.60 | 65.76 | 62.19 | 62.70 | 3.23M |
| Oct 2, 2026 | 66.45 | 66.91 | 64.49 | 65.60 | 2.65M |
| Oct 1, 2026 | 65.73 | 67.27 | 65.30 | 65.62 | 1.72M |
| Sep 30, 2026 | 65.90 | 66.92 | 65.25 | 65.91 | 2.98M |
| Sep 29, 2026 | 65.91 | 66.52 | 64.38 | 65.64 | 2.40M |
| Sep 28, 2026 | 64.58 | 66.41 | 64.25 | 66.16 | 2.55M |
| Sep 25, 2026 | 65.66 | 65.95 | 64.44 | 64.66 | 1.60M |
| Sep 24, 2026 | 65.37 | 66.47 | 64.89 | 65.66 | 1.84M |
| Sep 23, 2026 | 67.02 | 67.39 | 64.73 | 65.81 | 2.05M |
| Sep 22, 2026 | 68.07 | 69.56 | 67.48 | 67.59 | 2.39M |
| Sep 21, 2026 | 69.30 | 69.50 | 67.35 | 67.56 | 1.60M |
About Cytokinetics
Cytokinetics (CYTK) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOUTH SAN FRANCISCO, CA. Fiscal year ends December 31. SEC CIK 1061983.
CYTK board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Muna Bhanji | Director | May 27, 2026 |
| Robert I Blum | President & CEO | Sep 28, 2026 |
| James M Daly | Director | Jul 16, 2026 |
| John T Henderson | Director | Jul 16, 2026 |
| Robert Arthur Harrington | Director | Jul 16, 2026 |
| Edward M. Md Kaye | Director | Jul 16, 2026 |
| Robert E Landry | Director | Sep 15, 2026 |
| B Lynne Parshall | Director | Sep 1, 2026 |
| Wendell Wierenga | Director | Jul 16, 2026 |
| Nancy Wysenski | Director | Jul 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert I Blum | President & CEO | Sep 28, 2026 |
| Andrew Callos | EVP, Chief Commercial Officer | Aug 31, 2026 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | Mar 17, 2026 |
| Sung Lee | EVP, Chief Financial Officer | Jul 2, 2026 |
| Fady Ibraham Malik | EVP Research & Development | Sep 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 28, 2026 | Robert I Blum | Sale | 7,500 | $65.46 |
| Sep 28, 2026 | Robert I Blum | Sale | 7,500 | $65.46 |
| Sep 28, 2026 | Robert I Blum | Sale | 7,500 | $65.46 |
| Sep 28, 2026 | Robert I Blum | Sale | 7,500 | $65.46 |
| Sep 22, 2026 | Fady Ibraham Malik | Sale | 3,500 | $68.29 |
| Sep 22, 2026 | Fady Ibraham Malik | Sale | 3,500 | $68.29 |
| Sep 22, 2026 | Fady Ibraham Malik | Sale | 3,500 | $68.29 |
| Sep 22, 2026 | Fady Ibraham Malik | Sale | 3,500 | $68.29 |
| Sep 15, 2026 | Robert I Blum | Sale | 97,926 | $69.33 |
| Sep 15, 2026 | Robert I Blum | Sale | 97,926 | $69.33 |
| Sep 15, 2026 | Robert I Blum | Sale | 97,926 | $69.33 |
| Sep 15, 2026 | Robert I Blum | Sale | 97,926 | $69.33 |
| Sep 15, 2026 | Robert E Landry | Sale | 1,000 | $72.13 |
| Sep 15, 2026 | Robert E Landry | Sale | 1,000 | $72.13 |
| Sep 15, 2026 | Robert E Landry | Sale | 1,000 | $72.13 |
CYTK financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $88.04M | $-784.96M | -6.54 | $-510.01M |
| Dec 31, 2024 | $18.47M | $-589.53M | -5.26 | $-395.89M |
| Dec 31, 2023 | $7.53M | $-526.24M | -5.45 | $-414.33M |
| Dec 31, 2022 | $94.59M | $-388.95M | -4.33 | $-299.52M |
| Dec 31, 2021 | $70.43M | $-215.31M | -2.80 | $-142.52M |
Latest balance sheet: total assets $1.92B, total liabilities $2.10B, cash $255.27M (as of Jun 30, 2026).
CYTK earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $81.37 |
| May 5, 2026 | 8-K Item 2.02 (results) | $77.09 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $70.10 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $59.19 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $35.25 |
| May 6, 2025 | 8-K Item 2.02 (results) | $33.97 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $47.45 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
| Aug 3, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CYTK
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.